Cerevel valuation, funding and investors

Cerevel works in pharmaceutical research and development, based in Cambridge, United States. Founded in 2018, it has about 140 employees.

Pharmaceutical Products Debt

VALUATION · TODAY

$755M −10% after Growth

Range $100M – $2.38B · Grade D

TODAY

+12 MO

$2.00B

$4.00B

$6.00B

$8.00B

2019

2020

2021

2022

2023

2024

2025

2026

2027

Growth $350M

Growth $440M

Growth $125M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY140 employees

+0%6m growth

+0%1y growth

−42%2y growth

200

400

Data from Jan 2021

TODAY

Predicted in 1 yr $679M −10% vs today

Predicted next raise $151M if a round comes

Winding-down probability 46%

Last round: Growth · $125M · Apr 2021
Valuation at last round: $1.39B · implied
Headcount: 140
Grade: D
Founded: 2018

How VCMC values companies →

Cerevel valuation today

VCMC values Cerevel at $755M today, with a range of $100M to $2.4B and a grade of D. The valuation starts from its last funding round, a growth round in Apr 2021.

Valuation by date (110 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Cerevel: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2018	$9.05M	$3.29M – $24.9M	$12.4M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.29M	$3.38M – $25.5M	$12.7M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.52M	$3.47M – $26.2M	$13.1M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.78M	$3.56M – $26.9M	$13.4M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$10.0M	$3.65M – $27.6M	$13.8M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.3M	$3.75M – $28.3M	$14.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.6M	$3.85M – $29.1M	$14.5M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.9M	$3.96M – $29.9M	$14.7M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$11.2M	$4.06M – $30.7M	$14.8M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.5M	$4.17M – $31.5M	$14.9M (+30%)	before first round	–	unknown	D	0%
24 Oct 2018	$3.9B	$2.6B – $6.5B	$4.3B (+10%)	after a round	–	unknown	B	0%
1 Nov 2018	$3.9B	$2.6B – $6.5B	$4.3B (+10%)	after a round	–	unknown	B	0%
1 Dec 2018	$3.9B	$2.6B – $6.5B	$4.3B (+9%)	after a round	–	unknown	B	0%
1 Jan 2019	$4.0B	$2.6B – $6.5B	$4.3B (+8%)	after a round	–	unknown	B	0%
1 Feb 2019	$4.0B	$2.6B – $6.5B	$4.3B (+7%)	after a round	–	unknown	B	0%
1 Mar 2019	$4.0B	$2.6B – $6.5B	$4.3B (+6%)	after a round	–	unknown	B	0%
1 Apr 2019	$4.1B	$2.6B – $6.5B	$4.3B (+6%)	after a round	–	unknown	B	0%
1 May 2019	$4.1B	$2.6B – $6.5B	$4.3B (+5%)	after a round	–	unknown	B	0%
1 Jun 2019	$4.1B	$2.6B – $6.5B	$4.3B (+4%)	after a round	–	unknown	B	0%
1 Jul 2019	$4.2B	$2.6B – $6.5B	$4.3B (+3%)	after a round	–	unknown	B	0%
1 Aug 2019	$4.2B	$2.6B – $6.5B	$4.3B (+2%)	after a round	–	unknown	B	0%
1 Sep 2019	$4.2B	$2.6B – $6.5B	$4.3B (+1%)	after a round	–	unknown	B	0%
1 Oct 2019	$4.3B	$2.6B – $6.5B	$4.3B (+1%)	after a round	–	unknown	B	0%
1 Nov 2019	$4.3B	$2.5B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 Dec 2019	$4.3B	$2.4B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 Jan 2020	$4.3B	$2.3B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 Feb 2020	$4.3B	$2.2B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 Mar 2020	$4.3B	$2.1B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 Apr 2020	$4.3B	$2.0B – $6.5B	$4.3B (0%)	after a round	–	unknown	B	0%
1 May 2020	$4.3B	$1.9B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
1 Jun 2020	$4.3B	$1.8B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
1 Jul 2020	$4.3B	$1.7B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
1 Aug 2020	$4.3B	$1.6B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
1 Sep 2020	$4.3B	$1.5B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
1 Oct 2020	$4.3B	$1.5B – $6.5B	$4.3B (0%)	after a round	–	unknown	C	0%
28 Oct 2020	$4.8B	$3.4B – $7.5B	$5.3B (+10%)	after a round	–	unknown	B	0%
1 Nov 2020	$4.8B	$3.4B – $7.5B	$5.3B (+10%)	after a round	–	unknown	B	0%
1 Dec 2020	$4.8B	$3.4B – $7.5B	$5.3B (+9%)	after a round	–	unknown	B	0%
1 Jan 2021	$4.9B	$3.4B – $7.5B	$5.3B (+8%)	after a round	91	unknown	B	0%
1 Feb 2021	$4.9B	$3.4B – $7.5B	$5.3B (+7%)	after a round	91	unknown	B	0%
1 Mar 2021	$4.9B	$3.4B – $7.5B	$5.3B (+6%)	after a round	91	unknown	B	0%
1 Apr 2021	$5.0B	$3.4B – $7.5B	$5.3B (+6%)	after a round	91	unknown	B	0%
14 Apr 2021	$1.4B	$913M – $2.3B	$1.5B (+10%)	after a round	91	unknown	B	0%
1 May 2021	$1.4B	$913M – $2.3B	$1.5B (+9%)	after a round	91	unknown	B	0%
1 Jun 2021	$1.4B	$913M – $2.3B	$1.5B (+9%)	after a round	91	unknown	B	0%
1 Jul 2021	$1.4B	$913M – $2.3B	$1.5B (+8%)	after a round	91	unknown	B	0%
1 Aug 2021	$1.4B	$913M – $2.3B	$1.5B (+7%)	after a round	91	unknown	B	0%
1 Sep 2021	$1.4B	$913M – $2.3B	$1.5B (+6%)	after a round	91	unknown	B	0%
1 Oct 2021	$1.5B	$913M – $2.3B	$1.5B (+5%)	after a round	91	unknown	B	0%
1 Nov 2021	$1.5B	$913M – $2.3B	$1.5B (+4%)	after a round	91	unknown	B	0%
1 Dec 2021	$1.5B	$913M – $2.3B	$1.5B (+4%)	after a round	91	unknown	B	0%
1 Jan 2022	$1.5B	$913M – $2.3B	$1.5B (+3%)	after a round	91	unknown	B	0%
1 Feb 2022	$1.5B	$913M – $2.3B	$1.5B (+2%)	after a round	91	unknown	B	0%
1 Mar 2022	$1.8B	$1.1B – $2.8B	$1.8B (+3%)	after a round	200	growing	B	0%
1 Apr 2022	$1.8B	$1.1B – $2.8B	$1.8B (+1%)	after a round	200	growing	B	0%
1 May 2022	$1.8B	$1.1B – $2.8B	$1.8B (0%)	after a round	200	growing	B	0%
1 Jun 2022	$1.8B	$1.1B – $2.8B	$1.8B (0%)	after a round	200	growing	B	0%
1 Jul 2022	$1.8B	$1.1B – $2.8B	$1.8B (0%)	after a round	200	growing	B	0%
1 Aug 2022	$1.8B	$906M – $2.8B	$1.8B (0%)	after a round	200	unknown	B	0%
1 Sep 2022	$1.8B	$861M – $2.8B	$1.8B (0%)	after a round	200	unknown	B	0%
1 Oct 2022	$1.8B	$820M – $2.8B	$1.8B (0%)	after a round	200	unknown	C	0%
1 Nov 2022	$1.8B	$779M – $2.8B	$1.8B (0%)	after a round	200	unknown	C	0%
1 Dec 2022	$1.8B	$742M – $2.8B	$1.8B (0%)	after a round	200	unknown	C	0%
1 Jan 2023	$1.8B	$705M – $2.8B	$1.8B (0%)	after a round	200	unknown	C	0%
1 Feb 2023	$2.0B	$1.1B – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Mar 2023	$2.0B	$1.1B – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Apr 2023	$2.0B	$1.1B – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 May 2023	$2.0B	$1.0B – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Jun 2023	$2.0B	$1.0B – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Jul 2023	$2.0B	$996M – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Aug 2023	$2.0B	$984M – $3.0B	$2.0B (0%)	after a round	290	growing	B	0%
1 Sep 2023	$2.0B	$513M – $3.0B	$2.0B (0%)	after a round	290	unknown	C	0%
1 Oct 2023	$2.0B	$488M – $3.0B	$2.0B (0%)	after a round	290	unknown	C	0%
1 Nov 2023	$2.0B	$645M – $3.1B	$2.0B (-3%)	after a round	330	up	C	0%
1 Dec 2023	$2.0B	$624M – $3.1B	$2.0B (-4%)	after a round	330	up	C	0%
1 Jan 2024	$2.0B	$603M – $3.1B	$1.9B (-4%)	after a round	330	up	C	0%
1 Feb 2024	$2.0B	$582M – $3.1B	$1.9B (-4%)	after a round	330	up	C	0%
1 Mar 2024	$2.0B	$564M – $3.1B	$1.9B (-5%)	after a round	330	up	C	0%
1 Apr 2024	$2.0B	$548M – $3.1B	$2.0B (-4%)	after a round	340	up	C	0%
1 May 2024	$2.0B	$443M – $3.1B	$1.9B (-4%)	after a round	340	up	C	0%
1 Jun 2024	$2.0B	$425M – $3.1B	$1.9B (-4%)	after a round	340	up	C	0%
1 Jul 2024	$2.0B	$408M – $3.1B	$1.9B (-4%)	after a round	340	up	D	0%
1 Aug 2024	$2.0B	$306M – $3.0B	$1.9B (-7%)	after a round	340	flat	D	0%
1 Sep 2024	$493M	$270M – $1.1B	$302M (-39%)	after a round	240	shrinking	C	97%
1 Oct 2024	$472M	$257M – $1.1B	$289M (-39%)	after a round	240	shrinking	C	97%
1 Nov 2024	$451M	$244M – $1.1B	$277M (-39%)	after a round	240	shrinking	C	97%
1 Dec 2024	$384M	$206M – $923M	$235M (-39%)	after a round	140	shrinking	C	97%
1 Jan 2025	$367M	$196M – $895M	$225M (-39%)	after a round	140	shrinking	C	97%
1 Feb 2025	$351M	$186M – $867M	$216M (-38%)	after a round	140	shrinking	C	97%
1 Mar 2025	$337M	$178M – $843M	$212M (-37%)	after a round	140	shrinking	C	97%
1 Apr 2025	$322M	$169M – $817M	$212M (-34%)	after a round	140	shrinking	C	97%
1 May 2025	$319M	$161M – $900M	$212M (-33%)	after a round	140	shrinking	C	97%
1 Jun 2025	$305M	$153M – $876M	$212M (-30%)	after a round	140	shrinking	C	97%
1 Jul 2025	$293M	$146M – $853M	$212M (-27%)	after a round	140	shrinking	C	97%
1 Aug 2025	$280M	$138M – $829M	$212M (-24%)	after a round	140	shrinking	C	97%
1 Sep 2025	$268M	$132M – $807M	$212M (-21%)	after a round	140	shrinking	C	97%
1 Oct 2025	$257M	$125M – $786M	$212M (-17%)	after a round	140	shrinking	C	97%
1 Nov 2025	$246M	$119M – $764M	$212M (-14%)	after a round	140	shrinking	C	97%
1 Dec 2025	$236M	$113M – $744M	$212M (-10%)	after a round	140	shrinking	C	97%
1 Jan 2026	$225M	$108M – $724M	$212M (-6%)	after a round	140	shrinking	C	97%
1 Feb 2026	$216M	$102M – $704M	$212M (-2%)	after a round	140	shrinking	C	97%
1 Mar 2026	$354M	$100M – $2.2B	$354M (0%)	after a round	140	unknown	D	89%
1 Apr 2026	$401M	$100M – $2.2B	$401M (0%)	after a round	140	unknown	D	82%
1 May 2026	$450M	$100M – $2.3B	$377M (-16%)	after a round	140	unknown	D	76%
1 Jun 2026	$500M	$100M – $2.3B	$425M (-15%)	after a round	140	unknown	D	70%
1 Jul 2026	$550M	$100M – $2.3B	$474M (-14%)	after a round	140	unknown	D	64%
1 Aug 2026	$602M	$100M – $2.3B	$525M (-13%)	after a round	140	unknown	D	59%
1 Sep 2026	$653M	$100M – $2.3B	$576M (-12%)	after a round	140	unknown	D	54%
1 Oct 2026	$705M	$100M – $2.4B	$627M (-11%)	after a round	140	unknown	D	50%
24 Oct 2026	$755M	$100M – $2.4B	$679M (-10%)	after a round	140	unknown	D	46%

Key facts about Cerevel

Founded: 2018
Headquarters: Cambridge, United States
Employees: about 140 -58% in a year
Total raised: $1.22B
Funding rounds: 4
Last round: Debt Aug 2022

Cerevel was founded in 2018 by Morris Birnbaum.

Cerevel funding history

Cerevel has 4 funding rounds on record, from Oct 2018 to Aug 2022, $1.22B in total. None disclosed a valuation.

Debt 12 Aug 2022no round page
Investors not disclosed.
Sources: globenewswire.com, news.abbvie.com, goodwinlaw.com
$300M
Growth Equity 13 Apr 2021
With NovaQuest Capital Management, Bain Capital.
Sources: globenewswire.com, goodwinlaw.com, news.abbvie.com and 3 more
$125M
Growth Equity 27 Oct 2020
Led by Perceptive Advisors; with ARYA Sciences Acquisition Corp II, Adage Capital Management, Ally Bridge Group, Boxer Capital, EcoR1 Capital, Federated Hermes Kaufmann Small Cap Fund, Fidelity Management & Research Company, LLC, Invus, Novalis LifeSciences, RA Capital, Rock Springs Capital, Sphera Funds, Citadel, T. Rowe Price Associates, Inc., Bain Capital, Pfizer Inc..
Sources: novalislifesciences.com, news.abbvie.com, news.abbvie.com
$440M
Growth Equity 23 Oct 2018
Led by Bain Capital Private Equity; with Bain Capital Life Sciences, Bain Capital.
Sources: baincapital.com, biopharmadive.com, medcitynews.com
$350M

Cerevel investors

20 investors have backed Cerevel; Bain Capital Private Equity and Perceptive Advisors led at least one round.

Adage Capital Management
ARYA Sciences Acquisition Corp II
Bain Capital Life Sciences
Federated Hermes Kaufmann Small Cap Fund
Fidelity Management & Research Company, LLC
Invus
Pfizer Inc.
T. Rowe Price Associates, Inc.

What Cerevel does

Cerevel works in pharmaceutical products, with 7 recorded offerings and customers in pharmaceuticals and healthcare.

Cerevel Therapeutics Holdings, Inc. is an American pharmaceutical company engaged in the research and development of therapies for neurological and psychiatric disorders, as well as oncology. The company operates primarily in the pharmaceutical and biotechnology sectors, serving pharmaceutical companies, healthcare providers, and patients with neurological and psychiatric conditions. Cerevel also engages in sustainability initiatives and patient support programs.

Description from Veridion's company data.

Products and services

Pharmaceutical Research and Development
Neuroscience Therapies Development
Oncology Therapies Development
Mental and Neurological Illness Therapies Development
Pharmaceutical Product Commercialization
Scientific Advancement Services
Patient Support Services

Markets

Pharmaceuticals
Healthcare

Business model

Business-to-Business
Manufacturing

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about Cerevel

What is Cerevel worth?

Valuation $755M (range $100M to $2.4B), as of 24 Oct 2026.

Has Cerevel raised money?

Cerevel has 4 funding rounds on record, from Oct 2018 to Aug 2022, $1.22B in total. None disclosed a valuation.

Who has invested in Cerevel?

Bain Capital Private Equity, Perceptive Advisors, Bain Capital, Adage Capital Management, Ally Bridge Group and ARYA Sciences Acquisition Corp II, and 14 more. Lead investors include Bain Capital Private Equity and Perceptive Advisors.

How many people work at Cerevel?

About 140, down 58% over the last year. Headcount rose from 91 in Jan 2021 to 340 in Mar 2024, then fell to 140 in Nov 2024.

What does Cerevel do?

Cerevel works in pharmaceutical products, with 7 recorded offerings and customers in pharmaceuticals and healthcare. Its main offerings are pharmaceutical research and development, neuroscience therapies development and oncology therapies development.

When was Cerevel founded, and where is it based?

Cerevel was founded in 2018 and is based in Cambridge, United States. It has about 140 employees, down 58% over the last year.

How we value companies Report an issue